1. Pink Sheet
  2. >>Geography
  3. >>Europe

EMA Proposes Updating Hepatitis B Guide To Support Drugs Aiming For ‘Functional Cure’

 
• By Vibha Sharma

Since the European Medicines Agency adopted its hepatitis B guideline in 2006, the treatment goal of ‘functional cure’ has evolved and changed the development landscape of agents intended for the treatment of chronic infection.

Human hand hold care liver health therapy, Liver cancer, cancer, donation liver, disease, donation, Hepatitis, cirrhosis, Hepatitis B virus, HBV, Vaccine, insurance, hospital.World hepatitis day
Nearly 300 million people globally are living with chronic hepatitis B • Source: Shutterstock

The European Medicines Agency is inviting stakeholder feedback on plans to update its hepatitis B medicines guideline to clarify the requirements for new products that aim to achieve a “functional cure,” have novel mechanisms of action and/or are intended for finite (time-limited) or combination treatment approaches.

The EMA’s proposal is outlined in a draft concept paper in which the agency explains that its current guideline...

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Pink Sheet for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Europe

Semaglutide: EMA Safety Probe Confirms Rare Eye Disorder Risk

 
• By Neena Brizmohun

The EU product information for Novo Nordisk’s semaglutide medicines is to be updated to include non-arteritic anterior ischemic optic neuropathy as a side effect with a frequency of “very rare.”

Infographic: Leqembi – A Geographical Comparison

 
• By Anabel Costa-Ferreira

The Pink Sheet explores how regulatory approvals for Leqembi differ around the world, and looks at what is coming next.

UK MHRA: Bacteriophage Developers Wanted ‘More Clarity’ On UK Framework

 
• By Eliza Slawther

Julian Beach, interim executive director of healthcare quality and access at the UK drug regulator, the MHRA, tells the Pink Sheet how the agency is responding to increased efforts to develop bacteriophage therapies.

New Pricing Agreements And Greater Transparency: What A US MFN Policy Could Mean For France

 
• By Francesca Bruce

A potential MFN drug pricing policy in the US could also lead to a greater push for collaborative action in the EU, such as joint procurement among the member states, says one European industry expert.

More from Geography

Semaglutide: EMA Safety Probe Confirms Rare Eye Disorder Risk

 
• By Neena Brizmohun

The EU product information for Novo Nordisk’s semaglutide medicines is to be updated to include non-arteritic anterior ischemic optic neuropathy as a side effect with a frequency of “very rare.”

Infographic: Leqembi – A Geographical Comparison

 
• By Anabel Costa-Ferreira

The Pink Sheet explores how regulatory approvals for Leqembi differ around the world, and looks at what is coming next.

To Compete With China, US FDA Must Deregulate Early Gene Therapy Studies, CAR-T Inventor Says

 
• By Sarah Karlin-Smith

FDA regulation was painted as an obstacle to US dominance in the cell and gene therapy space even as panelists at an agency event praised the Office of Therapeutic Products' track record under Nicole Verdun.